Introduction
Autism is a syndrome with a broad spectrum of phenotypes characterized by deficits in social interaction and communication, repetitive or stereotyped behaviors, and restricted interests (Rutter, 2005) . Autism spectrum disorder (ASD) manifests mostly before 3 years of age (Klauck, 2006) . ASDs include two related diagnoses; pervasive developmental disorder (PDD) including atypical autism, impairment in the same areas, but not meeting criteria for autism; Asperger's syndrome, which is milder than PDD, showing similar impairments in social interaction, behaviors and interests, but no significant delay in linguistic and cognitive development (Weiss, 2009 ). The prevalence rate of ASDs is ~0.6% and ASDs are approximately four times more common in males than in females ). Many studies have been performed to elucidate the pathogenesis of ASDs, but identified risk factors do not explain a significant proportion of the disease prevalence. Genetic epidemiological data have been suggesting that ASDs are heritable both in autism families and in the general population (Freitag, 2007) . The concordance rates of autism in monozygotic twins were reported to be significantly higher (~ 60-90%) than those in dizygotic twins (~ 10%) and the recurrence rates are known to be approximately 10-20 times higher in siblings than in normal population (Folstein & Rosen-Sheidley, 2001 ; Cohen et al., 2005; Bailey et al., 1995; Lauritsen et al., 2005) . ASD is not a single-gene disorder with Mendelian inheritance but rather a component of various genetic disorders with apparent cytogenetic abnormalities (Eapen, 2011) . Cytogenetic alterations were detected in 7.4% of ASD (Vorstman et al., 2006) , and some of them have been suggested as causative factors of neurodevelopmental disorders (Merikangas et al., 2009 ). However, discrepancies in study results and diverse modes of inheritance have hindered the discovery of common genetic susceptibility factors to ASDs. For these reasons, despite the growing evidence supporting the genetic susceptibility to ASD development (Folstein & Rosen-Sheidley, 2001 ; VeenstraVanderWeele & , the genetic mechanisms of ASD is still largely unknown. Recent technical advance in microarray-based whole-genome analysis has enabled identification of common and rare genetic alterations associated with ASDs. Several recent studies have suggested that ASDs are associated with genetic variations including single nucleotide polymorphisms (SNPs) and copy number variations (CNVs), and that these genetic variations may work together (Veenstra- . For example, de novo CNVs were found in ~7% of idiopathic ASD families via oligoarray-comparative genomic hybridization and whole-genome SNP array analysis (Abrahams & Geschwind, 2008; Psychiatric GWAS Consortium Coordinating Committee et al., 2009). In addition to rare de novo variations, common genetic variations such as SNPs on 5p14.1 were found to be associated with ASDs and this finding was replicated in two independent studies ). Recently introduced next-generation sequencing (NGS) will further accelerate mining of genetic variations linked with ASDs (Ropers, 2010) . Graphical overview of the reported ASD-associated CNVs and SNP are illustrated in the Figure 1 . In this chapter, we will review the recent results of CNV and SNP genome-wide association studies (GWAS) on ASDs and discuss the perspectives of the genetic susceptibility study of ASDs. 
CNVs associated with ASD

What is CNV?
Using array-CGH, a combination of microarray and comparative genomic hybridization (CGH) technologies, two pioneering groups of scientists have identified wide-spread CNVs in apparently healthy, normal individuals in 2004 (Iafrate et al., 2004; Sebat et al., 2004) . CNV is defined as any type of genetic variant that alters the chromosomal structure, including duplications and deletions (Iafrate et al., 2004; Sebat et al., 2004; Redon et al., 2006) and now known to be one of the most prevalent types of genetic variations in the human genome Hurles et al., 2008; Carter, 2007; Estivill & Armengol, 2007) . In addition to SNPs, CNVs in normal individuals have been widening our understanding of genetic heterogeneity (Iafrate et al., 2004; Sebat et al., 2004; Redon et al., 2006) . Commonly used working definition of CNV was a copy number change involving a DNA segment sized 1 kilobases (kb) or larger . Nowadays, definition of CNVs includes any DNA structural variants including duplications, deletions and inversions (Hurles et al., 2008) . When the frequency of CNV is common (>1%) in the population, CNV is also called copy number polymorphism (CNP). However, due to lack of standardized technologies to define CNV, the size and frequency of CNV have not been well defined in human populations. Since the two pioneering studies discovered the evidence of the existence of CNVs ( CNVs can affect gene functions in several ways and have a potential to affect gene expression levels presumably larger than that of SNPs. Deletion or duplication may disrupt the genes located inside those regions, resulting in changes in the gene structure, which can affect the gene expression. Alternatively, disruption of the transcription regulatory regions and the enhancers can also affect the gene expression. During the recombination which is thought to be an important mechanism of CNV development, novel fusion products may be generated, which may exert positive or negative effects on gene expression and epigenetic regulations (Feuk et There have been many reports on CNVs associated with ASDs, but, due to technical limitations and lack of standardized methods for defining the CNVs and CNV regions (CNVRs), there are inconsistencies among studies which should be removed by further GWAS. 
CNVs in ASD
4X10 -4 ). A number of novel genes such as SHANK2, SYNGAP1, DLGAP2 and the DDX53-PTCHD1
in the CNVs were found to be associated with ASD in this study. Also, through gene set enrichment analysis, cellular proliferation, projection and motility, and GTPase/Ras signaling were found to be affected by the CNVs identified in their study. This approach demonstrated the new paradigm of autism research based on functional pathway and crosstalk.
SNPs in autism
Before the establishment of GWAS, the genome-wide linkage analysis has been used for the discovery of the mutations in diverse diseases (OMIM http://www.ncbi.nlm.nih.gov/omim). Location of the disease genes were successfully narrowed down by linkage disequilibrium mapping studies, but linkage approach was not always successful especially for complex diseases. In many cases, the significant linkage loci were not replicated. One potential reason is that the effect of a single risk variant on the pathogenesis of complex disease might be too small to be detected. Small genetic effects could be detected with greater power by association analyses such as GWAS with large case-control population (Risch & Merikangas, 1996) . In other words, to identify common risk alleles in the common complex diseases, population-wide analysis with more common and dense variants is required. SNP-GWAS can be an ideal approach for unbiased screening and also be adopted for high-density linkage analysis. SNP-GWAS became a matured technology for exploring novel associations between genetic variants and complex diseases because over 12 million of SNAs have been catalogued and high density array fabrication/analysis technologies have been developed. In neuropsychiatric disorders with unknown etiology such as ASD, SNP-GWAS have been actively adopted to explore the genetic background of the diseases (Table 2) . In this chapter, we will review the major SNP-GWAS results for ASDs. Table 2 . Genome-wide SNP association studies of autism
Common SNPs associated with ASD
Arking et al. performed a two-stage study on ASD using genome-wide linkage and familybased association mapping by whole-genome SNP genotyping (Arking et al., 2008) . For stage I, they selected 72 multiplex ASD families and genotyped the samples using Affymetrix 500K arrays. In this approach, they could not find any significant SNPs or haplotypes. However, through the genome-wide linkage analysis, they identified 2 significant loci associated with ASD, 7q35 and 10p13-14. In the most significant locus (7q35), they identified that a polymorphism in contactin-associated protein-like 2 (CNTNAP2) gene, a member of the neurexin superfamily, is associated with ASD. In the second stage, they validated the significant findings of the stage I by examining 145 multiplex families and confirmed that CNTNAP2 was an autism-susceptibility gene. This result was the first evidence that a common genetic variant in the neurexin superfamily member increases risk of autism. In 2009, Weiss et al. explored a linkage and SNP association analysis with 1,031 multiplex autism families using Affymetrix 5.0 SNP array . They found that a SNP on 5p15 locus between SEMA5A and TAS2R1 gene was significantly associated with autism. In addition, the expression of SEMA5A was found to decrease in brains of autistic patients. Taken together the authors suggested a possibility of SEMA5A as an autism risk gene. Wang et al. used higher density SNA array and larger study populations to identify common genetic risk factors underlying ASDs . They used two different sets of study subjects in discovery stage using Illumina Human 1M beadchip. First set was 780 families with 1,299 affected children and the second set was 1,204 patients and 6,491 controls. They identified six significant SNPs located between cadherin 10 (CDH10) and cadherin 9 (CDH9) genes strongly associated with ASD. These two genes encode neuronal cell-adhesion molecules. Among the 6 SNPs, the most significant one was rs4307059 (P = 3.4 × 10 −8 , odds ratio = 1.19). The SNP was replicated in two independent datasets of 447 families and 108 case-540 control sets. Combined analysis using all four datasets showed that all six SNPs are associated with autism (P values ranging from 7.4 × 10 −8 to 2.1 × 10 −10 ). Interestingly, 5p14.1 was consistently suggested as a novel risk locus in an independent study in the same year. Ma et al. performed GWAS with 438 Caucasian autistic families using Illumina Human 1M beadchip ). They found that 96 SNPs were strongly associated with autism (P < 0.0001). They validated all 96 significant associations in independent samples of 487 families using 550K Illumina BeadChip, which was the same array platform to Wang et al's. A novel locus on 5p14.1 was found to be significantly associated with autism both in the discovery and validation dataset. The Autism Genome Project (AGP) Consortium performed high-resolution genotyping with 1,558 families to identify significant SNPs (Anney et al., 2010). For primary analysis, they partitioned the dataset along axes of diagnosis and ancestry; spectrum versus strict; European versus all ancestries. Based on these partitioned data, they conducted four GWAS. They observed the strongest association for SNP rs4141463 in one of the four primary association analyses. Located within MACROD2, this marker crossed the GWA significance threshold of P < 5 x 10 -8 . They are performing analysis of combining data to validate the results of the primary analysis. Despite the expected advantages of large-scale GWAS analysis, none of the candidate associations have been replicated so far, which may underscore the genetic and phenotypic heterogeneity of ASD and indicate the fact that the effect size of common alleles contributing to common disorders is much smaller than expectation (Eapen, 2011).
Rare SNPs associated with ASD
Definition of a rare variant is a variant with frequency <1%. The most deleterious variants might be naturally eliminated during evolution, but some remain as rare variants. In 'common disease-common variant' model, most of the rare SNP associations have been missed by current GWAS concept. However, rapid development of NGS will facilitate the discovery of rare variants. Rare SNP associations are more likely to be detected by resequencing of relevant regions in hundreds or thousands of individuals. It is anticipated that advances in re-sequencing technologies will make it feasible to search systematically for rare variant effects.
Conclusion
Human Genome Project has provided insight into a complete sequence of the haploid human genome and we also have got new insight of the human genetic variations. Based on this new insight, conventional target gene oriented and hypothesis-driven research design has been quickly moved to a new paradigm, hypothesis-free mining of novel disease associated genes. Indeed, over hundreds of genetic variants which may affect the susceptibility of pathogenesis of complex disease have been identified by the GWAS. The GWAS have been actively adopted in studying the causative factors of neurodevelopmental disorders including ASD. Through GWAS approach, several robust ASD-associated variants in the genes such as NRXN1, SHANK3, NLGN4 and CNTNAP2 were uncovered. However, it is too early to say that GWAS have brought reliable-enough insight into ASD. Many of the significant CNVs identified in one study were not consistent or not successfully replicated in the following studies. New improved algorithms for CNV and CNVR will be needed for defining the CNVs more robustly. To sort out the platform to platform variation of CNV call, which is one of the obstacles for the meta-analysis, more reliable experimental methods should be developed. Re-sequencing large number of individuals without CNVs will help to discover the new rare variants. Considering the speed of technological innovations including algorithm, high-throughput analysis and NGS, we anticipate that current obstacles of GWAS in autism research will be removed soon. However, GWAS result itself will not be enough to get clinically applicable insight about the pathophysiology of ASD.
Integration of GWAS data with other resources such as improved bio-imaging, personal whole-genome sequencing, gene-environmental interaction and metagenome analysis data about gastrointestinal commensal bacteria will enable us to get a more comprehensive insight in designing future personalized care of autism. 
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